Article Figures & Tables
Figures
Figure 1: Selection of studies for inclusion in the meta-analysis of the use of aprotinin and lysine analogues in cardiac surgery. Note: ISPOT = International Study of Perioperative Transfusion.
Figure 2: Meta-analyses of myocardial infarction in placebo or inactive randomized controlled trials of the use of aprotinin in cardiac surgery (I2 = 0%, Z = 0.46). References available in Appendix 1 (www.cmaj.ca/cgi/content/full/180/2/183/DC2). Note: CI = confidence interval, NA = not applicable.
Figure 3: Meta-analyses of myocardial infarction in placebo or inactive randomized controlled trials of the use of tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) in cardiac surgery (TXA v. control I2 = 0%, Z = 0.41; EACA v. control I2 = 12.4%, Z = 0.25; aprotinin, TXA and EACA v. control I2 = 0%, Z = 0.66). References available in Appendix 1 (www.cmaj.ca/cgi/content/full/180/2/183/DC2). Note: CI = confidence interval, NA = not applicable.
Figure 4: Meta-analyses of myocardial infarction in head-to-head randomized controlled trials of the use of aprotinin and tranexamic acid (TXA) in cardiac surgery (I2 = 0%, Z = 0.02). References available in Appendix 1 (www.cmaj.ca/cgi/content/full/180/2/183/DC2). Note: CI = confidence interval, NA = not applicable.
Figure 5: Meta-analyses of mortality in randomized placebo or inactive controlled trials of aprotinin (I2 = 0%, Z = 0.49). References available in Appendix 1 (www.cmaj.ca/cgi/content/full/180/2/183/DC2). Note: CI = confidence interval, NA = not applicable.
Figure 6: Meta-analyses of mortality in randomized placebo or inactive controlled trials of tranexamic acid (TXA) and epsilon aminocaproic acid (EACA) (TXA v. control I2 = 0%, Z = 1.43; EACA v. control I2 0%, Z = 0.83; aprotinin, TXA and EACA v. control I2 = 0%, Z = 0.73. References available in Appendix 1 (www.cmaj.ca/cgi/content/full/180/2/183/DC2). Note: CI = confidence interval, NA = not applicable.
Figure 7: Meta-analyses of mortality in head-to-head randomized controlled trials of the use of aprotinin and tranexamic acid (TXA) in cardiac surgery (I2 = 0%, Z = 1.85). References available in Appendix 1 (www.cmaj.ca/cgi/content/full/180/2/183/DC2). Note: CI = confidence interval, NA = not applicable.
Figure 8: Meta-analyses of mortality in head-to-head randomized controlled trials of the use of aprotinin and epsilon aminocaproic acid (EACA) in cardiac surgery (I2 = 0%, Z = 1.86). References available in Appendix 1 (www.cmaj.ca/cgi/content/full/180/2/183/DC2). Note: CI = confidence interval, NA = not applicable.